Background {#Sec1}
==========

Acute febrile illnesses are the most common presentation of young children attending outpatient settings worldwide \[[@CR1]\]. Like in well-resourced settings, the majority of acute febrile illnesses are caused by viral pathogens requiring minimal supportive intervention; serious bacterial infections (SBI) have become increasingly rare with improving vaccination coverage and hygiene \[[@CR2], [@CR3]\]. However, the lack of adequate diagnostic tools makes it difficult to differentiate these viral diseases from the minority of children with SBI. Children with serious bacterial infections (SBI) often present with non-specific clinical signs and several concomitant symptoms \[[@CR4]\]. Sub-standard management of children with infections has resulted in persistent high mortality from common childhood infections \[[@CR5]\] and high-volume over-prescription of antibiotics \[[@CR6]\].

Health workers rely on the World Health Organization (WHO) Integrated Management of Childhood Illnesses (IMCI) algorithm, which recommends presumptive treatment based on clinical signs and symptoms (besides the rapid diagnostic test for malaria that was introduced in the 2014 version, \[[@CR7]\]). The Integrated Community Case Management guidelines (iCCM) is a simplified version of IMCI, geared towards community health workers \[[@CR8], [@CR9]\]. Due to the lack of available evidence when IMCI was initially developed, the algorithm was based mainly on expert opinion in addition to small derivation studies \[[@CR10]\]. Though IMCI and iCCM have been implemented globally, their performance in detecting children with SBI has not been validated to date using stringent microbiological methods, instead of expert clinical diagnosis (and chest radiograph (CXR) in some studies) \[[@CR11], [@CR12]\]. Adherence to IMCI has been low. The reasons for nonadherence to IMCI are numerous and complex \[[@CR13], [@CR14]\], but one important aspect is the content: for example, IMCI lacks guidance in key areas, e.g. for patients with fever without clinical focus \[[@CR7]\]. As a result, clinicians over-prescribe antibiotics out of the fear of missing patients with SBI \[[@CR15]\]. Therefore, there is a need to improve current management guidelines for the primary care management of acute febrile illnesses, including evidence from economically developed countries. Here, a series of clinical and laboratory prediction rules and clinical guidelines, with different degrees of validation, have been designed for the management of febrile children in the ambulatory setting \[[@CR16]--[@CR27]\]. There is a growing body of evidence that the causes of acute non-malaria febrile illnesses in children in low- and high resource settings are in fact quite similar \[[@CR2]\]: cosmopolitan viruses and bacteria are the causative agent in the vast majority of cases while tropical pathogens cause only a minority of febrile episodes at the outpatient level. Clinical signs and laboratory tests from such clinical prediction rules and guidelines developed in well-resourced countries may thus also be useful for detecting SBI in children in low-resource settings. However, external validation to support their use in resource-poor settings is lacking. This is especially important because of differences in clinical presentations (e.g. malaria co-infection), the health care system (e.g. access to care, the possibility of safety netting, the level of training of primary care providers).

Methods {#Sec2}
=======

Aim {#Sec3}
---

The aim of this study was to estimate the diagnostic accuracy of existing prediction rules and clinical guidelines, including IMCI and iCCM, in identifying children with SBI in a resource-poor setting.

Design {#Sec4}
------

We performed an external, retrospective validation study of existing prediction rules and guidelines on a dataset collected prospectively in Tanzania that contains children aged 2 months to 10 years with fever presenting to outpatient care \[[@CR2]\].

Participants/ setting {#Sec5}
---------------------

The study population comprised 1005 children from a study on causes of fever in rural and urban Tanzania, the 'Tanzanian Fever Study' \[[@CR2]\]. Briefly, children aged 2 months to 10 years with fever (axillary temperature of ≥38 °C) were enrolled consecutively at two outpatient clinics in 2008. Children with severe acute malnutrition and/or those requiring immediate live-saving procedures were excluded. This was partly for safety reasons, but also because WHO recommends antibiotic treatment for all febrile children with severe acute malnutrition as these patients have a distinct immune response putting them at high risk of SBI \[[@CR7], [@CR28]\]. All participants in the dataset, including children with malaria infection, were included into the validation exercise. We performed sensitivity analyses to assess the influence of malaria co-infection on the diagnostic performance (see below).

Outcome definition {#Sec6}
------------------

The outcome, SBI, i.e. a bacterial infection requiring antibiotic treatment, was defined as presence of one of the following: bacteremia (positive blood culture for a known pathogen), *Salmonella typhi* infection (positive blood-or stool culture, or positive specific IgM rapid diagnostic test), radiographic pneumonia, urinary tract infection (positive urine dipstick and urine culture), meningitis, bacterial gastroenteritis (positive stool culture), significant skin/soft tissue infections and other systemic bacterial infections not routinely detected by blood culture (rickettsiosis, coxiellosis, and leptospirosis). Definitions were based on the methodology used in the 'Tanzania Fever Study': for each patient, the final diagnosis (or diagnoses) was established with a computer-generated algorithm based on pre-defined clinical and microbiological criteria \[[@CR2]\]. These criteria were derived from international guidelines as well as systematic reviews.

Clinical and laboratory assessment {#Sec7}
----------------------------------

Investigators used standardized case report forms to record clinical findings, including 23 symptoms and their respective duration, potential travel history and/or sick contacts, known chronic conditions, and 49 clinical signs. At the initial visit a systematic set of investigations was performed according to predefined algorithm; malaria testing was done for all children \[[@CR2]\]. If a clinical or laboratory diagnosis could not be made at the initial visit, a follow-up visit was scheduled for day 7 that included a full clinical and laboratory assessment for patients with persistent symptoms. In all cases, blood samples and pooled nasal and throat swabs were taken for microbiologic testing (cultures and rapid tests) on site and further serologic and molecular work-up in Switzerland and the USA. A complete blood cell count, including white blood cell count was done on site for all children. C-reactive protein (CRP) and procalcitonin (PCT) were performed retrospectively on stored samples by ELISA as detailed elsewhere \[[@CR29]\]. CXR were performed in the subgroup of cases fulfilling the WHO clinical definition of pneumonia \[[@CR30]\]. The diagnosis of radiological pneumonia was made in cases where CXR showed 'primary endpoint consolidation' according to WHO's Pneumococcal Trialist Ad Hoc Committee recommendations \[[@CR31]\]. If the IMCI clinical criteria for a suspected human immunodeficiency virus (HIV) infection were present, voluntary HIV testing was recommended to the child's guardian.

Selection of prediction rules and guidelines {#Sec8}
--------------------------------------------

All available prediction rules (laboratory and clinical) for identifying any SBI in children in the outpatient settings were identified through a structured literature review in Medline and Embase as part of the development of a novel disease management algorithm \[[@CR32]\]. The search strategy is detailed in the Additional file [1](#MOESM1){ref-type="media"} of the publication. The search was modified based on previously published systematic review and a European validation study \[[@CR16], [@CR33]\]. Prediction rules and guidelines that target the neonatal period, i.e. \< 3 months, were excluded. We also did not include prediction rules that primarily aim at predicting death (such as the PEDIA \[[@CR34]\], LODS \[[@CR35]\], and SICK \[[@CR36]\] scores) or the need for referral to the pediatric intensive care unit at in-patient level. Scores aimed at identifying dehydration for patients with gastroenteritis, or at detecting children with meningitis (there were only 2 patients with meningitis) were also not included. When variables of the dataset were not entirely matching the variables of the original rule or guideline, we identified proxies where possible (Additional file [2](#MOESM2){ref-type="media"}: Table S1). When more than 20% of the required variables were not recorded in the dataset (systematically missing), the rule/guideline was not included in the validation. This was based on the assumption that missing systematically more than 20% of predictor variables was not clinically sensible. Missing data on variables used in the validation were not imputed because the necessary missing-at-random assumption was likely to be incorrect given that all data was collected based on a predefined algorithm. We report the number of observations available for analysis of each prediction rule after application of the above assumptions. Where rules generated sum scores, previously published cut-offs were applied.

Statistical analysis {#Sec9}
--------------------

We used the Standard for Reporting of Diagnostic Accuracy (STARD) guidelines for study reporting \[[@CR37]\]. The accuracy of the included prediction rules and guidelines was estimated retrospectively in the prospectively collected 'Tanzania Fever Study' dataset by calculating sensitivity, specificity, and likelihood ratio (LR). For the low prevalence outpatient setting we considered a score helpful to rule-in SBI if, when positive, they substantially raised the probability of SBI (LR+ greater 5). Scores were deemed helpful for ruling-out SBI if, when negative, they substantially lowered the probability of illness (LR- lower than 0.2).

Clinical features were deemed warning signs if, when positive, they substantially raised the probability of illness---i.e., positive likelihood ratio of more than 5.0. Clinical features were deemed rule-out signs if, when negative, they substantially lowered the probability of illness---i.e., negative likelihood ratio of less than 0.2.

We performed the following sensitivity analyses by comparing the 95% confidence intervals (CIs) of diagnostic accuracy measures: First, to assess the influence of age range, we compared the target age group of the rules/ guidelines with those of the entire validation dataset. Second, as some predictors (fast breathing in IMCI, iCCM, and ALMANACH, and a positive CXR in the American Academy of Emergency Physicians \[AAEP\] guideline) were part of the diagnostic criteria for pneumonia in the validation dataset, we compared the full dataset with a dataset excluding pneumonia cases for these 4 guidelines. The same was done for UTI for prediction scales and guidelines that use urinary dipstick (Bleeker Score, Lab Score, ALMANACH and AAEP). Third, since malaria is known to raise CRP values \[[@CR38]\], we compared malaria negative patients with the full dataset for prediction rules that contain CRP. Fourth, for prediction rules that were originally derived for children with fever without source, we compared the full dataset with the dataset containing children with fever without source only. All analyses were performed with Stata version 13.1. The confidence intervals were calculated using the Stata diagt procedure (<http://www.stata.com/stb/stb59/sbe36_1/diagt.hlp>. We used a web-based tool to generate Venn diagrams (<http://jura.wi.mit.edu/bioc/tools/venn.php>).

Results {#Sec10}
=======

Prediction rules and guidelines {#Sec11}
-------------------------------

Through the structured literature review \[[@CR32]\], we identified 34 prediction rules/guidelines for the use in febrile children. Sixteen were designed to predict SBI at the outpatient level (Fig. [1](#Fig1){ref-type="fig"}, Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Fig. 1Flowchart of scores identified and considered for validation (adapted from \[[@CR32]\]). Pediatric intensive care unit (PICU) Table 1Clinical and laboratory prediction rules for management of acute febrile illnesses in children^a^Name of Prediction RuleAge GroupPredictorsDerivation studyAll serious infections Yale Observation Scale0-24 mQuality of CryReaction to parents' stimulationState VariationColorHydrationResponse to social overturesMcCarthy et al. \[[@CR39]\]Strong OR not crying(1)Cries briefly (1)Stays awake (1)Pink (1)Skin normal (1)Smiles OR Alert (1)Whimpering (3)Cries on/off (3)Awakes with stimulation (3)Pale extremities (3)Dry mouth (3)Brief smile OR alerts briefly (3)Weak (5)Continual cry (5)Falls to sleep (5)Pale OR cyanotic (5)Skin doughy (5)No smile OR face anxious (5)Sum of all six feature values (cut-offs used in literature: 8, 9 or 10) Five Stage Decision Tree0--16 yClinician instinct that something is wrongDyspneaTemperature \> 39.95 °CDiarrheaAge 15-25 mVan den Bruel et al. \[[@CR17]\]No0No or unknown0No0No or unknown0No or unknown0Yes or unknown1Yes1Yes1Yes1Yes1If yes to any of these five features Bleeker0-36 mDuration feverDays (points)H/o vomitingIll appearanceChest wall retractions+ tachypneaPoor peripheral circulationWBCCRP (mg/l)Urine WBCBleeker et al. \[[@CR18]\]0.5 (0), 1(2), 1.5 (4),2--2.5(5), 3--3.5(6), 4--4.5(7), 5--6(8), 6.5--8.5(9), ≥ 9(10)Y = 5Y = 4Y = 12Y = 7\< 10(0), 10--19(2), 20--29(4), 30--39(6), ≥ 40(8)Divide value by 10 and round to lower integer, max. = 16 points≥ 70 WBC/μl =9Total points, described cutoffs: clinical: 10, lab: 8 Thayyil1-36 mPCT (ng/ml)CRP (mg/l)WBCThayyil \[[@CR19]\]\> 2\> 50\> 15Cutoff: All positive Lab Score7d-36 mPCT (ng/ml)CRP (mg/l)Urine DipstickGaletto-Lacour \[[@CR20]\]\< 0.5 (0), ≥0.5 (2), ≥2 (4)\< 40 (0), 40--99 (2), ≥100 (4)Positive leucocyte or nitriteCutoff: 3 AUS fever model0--5 yGeneral appearance, cough, temperature, breathing difficulty, abnormal chest sounds, chronic disease, capillary refill time, urinary symptoms, respiratory rate, chest crackles, pneumococcal vaccine, heart rate, felt hot, meningococcal vaccine, infectious contacts, crying, fluid intake, respiratory symptoms, diarrhea, bulging fontanel, male, focal bacterial infection, abnormal ear, nose, and throat signs, age rash, stridor, wheezeCraig et al. \[[@CR21]\]Model risk estimate SBI risk score1 m-15yDevelopmental delayInfection risk factorState variationT (°C)CRTHydrationTachypnea^b^HypoxiaBrent et al. \[[@CR22]\]No (0)Yes (4)No (0),Yes (2)Eyes open (0)Eyes close briefly (1)Falls asleep (2)\< 37.5 (0),37.5--38.3 (1)≥38.4 (2)\< 2 (0)≥2 (2)Well hydrated (0)Dry mucous membranes (2)Reduced skin turgor (4)No (0)Yes (1)No (0)Mild (1)Severe (2) Rotterdam Fever model1 m-16yAge \< 1, Sex, Duration of Fever, Height of Fever, Tachypnea, Tachycardia, SaO2 \< 94%, CRT \> 3 s, Chest Wall retraction, Ill-appearance, CRPNijman et al. \[[@CR23]\]Model risk estimatePneumonia Pneumonia Rule n°10--16 yParental concern illness is differentShortness of breathVan den Bruel et al. \[[@CR17]\] ValuesIf yes to any of these two features Pneumonia Rule n°20-21ySaO2Triage TWheezeDecreased breath soundsFocal ralesChest painHistory of feverNeuman et al. \[[@CR24]\] ValuesClassification of Regression Tree/ clinical model Pneumonia Rule n°31-16yGruntingCoughRalesDecreased breath soundVomitingBilkis et al. \[[@CR25]\]Model risk estimate*bpm* Beats per minute, *CRT* Capillary refill time, *CRP* C-reactive protein, *h/o* History of, *m* Months, *SaO2* Oxygen saturation, *PCT* Procalcitonin, *RR* Respiratory rate, *T* Body temperature, *Y* Yes, *y* Years, *WBC* White blood cell count^a^Modified and appended from Verbakel et al. \[[@CR33]\]^b^Advanced pediatric life support cutoff Table 2Guidelines for management of acute febrile illnesses in children^a^Name of guidelineAge GroupClinical and laboratory featuresPublicationIMCI2 m-5yCNSHydration/ nutritionRespiratoryOther Danger signs- Lethargic or unconscious-h/o convulsions or currently seizing-stiff neck- Vomits everything-Unable to drink/ breastfeed-Severe malnutrition AND medical complications OR feeding issue-Severe dehydration (Two of the following)\--Lethargic or unconscious\--Sunken eyes\--Not able to drink or drinking poorly\--Reduced skin turgor- Stridor in a calm child-SaO2 \< 90% on RA (if available)-Chest indrawing and HIV positive-Tender swelling behind ear-Severe palmar pallor-Severe complicated measlesWHO \[[@CR7]\] Indications for antibiotic treatment-Uncomplicated severe malnutrition-Cough and tachypnea and/or chest indrawing after trial of bronchodilator (2-12 m: RR \> 50/min; ≥12 m: RR \>  40/min)-Ear pain or ear discharge \< 14 days-Blood in stoolIf yes to any of the danger signs: referral and IM antibioticsIf yes to any of the antibiotic signs: oral antibiotic treatmentiCCM2 m-5yCNSHydration/ nutritionRespiratoryOther Danger signs- Lethargic or unconscious-h/o convulsions or currently seizing-Vomits everything-Unable to drink/ breastfeed-Severe malnutrition (low MUAC or bilateral edema)-Chest indrawing-HIV positive-Blood in stoolWHO \[[@CR40]\] Indications for antibiotic treatment-Cough and tachypnea(2-12 m: RR \> 50/min; ≥12 m: \> 40/min)If yes to any of the antibiotic signs; oral antibiotic treatmentIf yes to any of the danger signs: referral and oral antibioticsALMANACH2 m-5yCNSHydration/ nutritionRespiratoryOther Danger signs- Lethargic or unconscious-h/o convulsions or currently seizing-stiff neck-Vomits everything-Unable to drink/ breastfeed-Severe wasting-Severe dehydration (Two of the following)\--Lethargic or unconscious\--Sunken eyes\--Not able to drink or drinking poorly\--Reduced skin turgor-Chest indrawing-Stridor in a calm child-Cyanosis-Tender swelling behind ear-Severe pallor-Jaundice-Severe soft tissue infectionRambaud-Althaus et al. \[[@CR9]\] Indications for antibiotic treatmentCough and RR \> 50/minAcute ear dischargeBlood in stoolUrine dipstick (Positive leucocyte or nitrite)Abdominal tendernessIf yes to any of the antibiotic signs; oral antibiotic treatmentIf yes to any of the danger signs: referral and IM antibioticsNICE traffic light system0-5yColorActivityRespiratoryCirculation and HydrationOtherNICE: Feverish Illness in Children \[[@CR26]\] Red- high risk- Pale/mottled/Ashen/blue-No response to social cues-Appears ill to healthcare professional-Does not wake or if roused does not stay awake-Weak high-pitched or continuous cry- Grunting- RR \> 60/min- Moderate/severe chest indrawing- Reduced skin turgor- Age 0-3 m & T ≥ 38 °C- Non-blanching rash- Bulging fontanel- Neck stiffness- Status epilepticus- Focal neurological signs- Focal seizures Amber- intermediate risk- Pallor- Not responding normally to social cues- Wakes only with prolonged stimulation- Decreased activity- No smile- Nasal flaring- Tachypnea(6-12 m: RR \> 50/min; \> 12 m: \>  40/min)- SaO2 ≤ 95%- Crackles-Tachycardia(\< 12 m: \> 160 bpm; 12-24 m: \> 150 bpm; 2-5y: \> 140 bpm)- Dry mucous membranes- Poor feeding in infants- CRT ≥ 3 s- Reduced urine output- fever ≥5 days- swelling of a limb or joint- non-weight bearing limb/not usingextremity- age 3-6 m, T ≥ 39 °C ValuesIf yes to any of these 5 categories, each scoring 2 to 13 featuresAmerican Academy of Emergency Physicians Guidelines3--36 mIll appearingPositive chest radiography (to be obtained if:T ≥ 39 °Cand WBC \> 20 K/mm3 or "clinical evidence of lower respiratory infection"Positive urine leucocyte + nitrite (to be obtained in male \< 1 year and female \< 2 year)T ≥ 39 °CAnd WBC \> 15 K/mm3American Academy of Emergency Physicians \[[@CR27]\] ValuesIf yes to any of these features*bpm* Beats per minute, *CRT* Capillary refill time, *CRP* C-reactive protein, *h/o* History of, *m* Months, *SaO2* Oxygen saturation, *PCT* Procalcitonin, *RR* Respiratory rate, *T* Body temperature, *Y* Yes, *y* Years, *WBC* White blood cell count^a^Modified and appended from Verbakel et al. \[[@CR33]\]

The NICE guideline is intended to predict 'serious disease' among children with acute febrile illness, and not to indicate antibiotic treatment. However, given that it was the only guideline designed for the use by healthcare professionals in primary care with various levels of training, we decided to include it in the validation exercise. In addition to the prediction rules and guidelines from the systematic review and European validation study \[[@CR16], [@CR33]\], we found one additional prediction rule for diagnosis of SBI \[[@CR21]\], two prediction rules for pneumonia \[[@CR24], [@CR25]\], and four clinical guidelines (AAEP, IMCI, iCCM, and ALMANACH \[[@CR7], [@CR8], [@CR27], [@CR41]\]). ALMANACH is an improved IMCI-based algorithm that includes urinary dipstick testing \[[@CR9]\]. Additional file [2](#MOESM2){ref-type="media"}: Table S1 displays whether the prediction rules and guidelines could be used for retrospective validation, as well as proxies for certain predictor variables used. For the prediction rules, validation was possible for the Bleeker Score, Thayyil Score, Lab Score and the Rotterdam Fever Model. More than 20% of predictors were missing systematically for other prediction rules, including 3 pneumonia rules. All clinical guidelines identified could be used for validation. Table [3](#Tab3){ref-type="table"} displays the prediction rules and guidelines that could be included into validation exercise. It also details the categories of SBI that were considered for the initial derivation or development of each rule/guideline. Table 3Prediction rules and guidelines that could be used for validation and SBI considered for each rule in the original derivation study/ at developmentPrediction rule/guidelinesSBI categories consideredMeningitisPneumoniaBacteremiaUTITyphoidCellulitis/ AbscessBacterial gastroenteritisLeptospirosisIntracellular bacteriaOtherBleeker✓✓✓✓✓^a^✓Osteomyelitis, EthmoiditisThayyil✓✓✓✓✓^a^Any positive bacterial culture from an otherwise sterile siteLab Score✓✓✓✓^b^✓^a^✓Rotterdam fever model^c^✓✓✓✓✓^a^✓✓OsteomyelitisIMCI✓✓✓✓✓✓✓✓✓iCCM✓✓✓✓✓✓✓✓✓ALMANACH✓✓✓✓✓✓✓✓✓NICE✓✓✓✓✓✓✓OsteomyelitisAAEP✓✓✓✓✓✓✓Osteomyelitis^a^Bacteremia only^b^Pyelonephritis was defined as positive urine culture and positive DMSA scan^c^Admission to the hospital was a pre-requisite for definition of SBI

Validation dataset {#Sec12}
------------------

The full details on the demographic and clinical characteristics of the study population are provided in the original study report \[[@CR2]\]. A SBI was identified in 16% (162/1005) of patients in the validation dataset (Table [4](#Tab4){ref-type="table"}). Table 4Cross table of serious bacterial infection (SBI) categoriesSBI categories, % (n), *N* = 1005MeningitisPneumoniaBacteremiaUTITyphoidCellulitis/ AbscessBacterial gastroenteritisLeptospirosisIntracellular bacteriaMeningitis0.2 (2)00000000Pneumonia3.1 (31)000.4 (4)0000Bacteremia^a^1.7 (18)0.4 (4)0.4 (4)00.1 (1)00UTI5.9 (59)0.1 (1)0000Typhoid3.7 (37)00.2 (2)00Cellulitis/ Abscess0.5 (5)000Bacterial gastroenteritis1.4 (14)00Leptospirosis0.4 (4)0Intracellular bacteria1.1 (11)^a^ positive blood culture for a known pathogen other than *Salmonella typhi*

Validation results {#Sec13}
------------------

The diagnostic accuracy for all included prediction rules and guidelines was low to moderate (Table [5](#Tab5){ref-type="table"}). The Bleeker rule, Rotterdam Fever Model (2.5% risk cutoff), and NICE guidelines had the highest sensitivity, ranging from 77.3 to 83.7%. However, the specificity of the Bleeker score was only 40.8% (95% CI 36.9--44.9%), and those of the Rotterdam Fever Model (2.5% risk cutoff), and NICE guidelines even lower: 35.6% (95% CI 32.4--39.0%) and 25.2% (95% CI 22.6--28.6%), respectively. IMCI (like iCCM) had a very low sensitivity of 37.0% (95% CI 29.4--44.6%) and a moderate specificity of 70.3% (95% CI 67.1--73.4%). Compared to IMCI, ALMANACH had a higher sensitivity of 63.3% (55.4--70.6%). However, ALMANACH's specificity was lower compared to IMCI (63.2, 95% CI 59.8--66.4%). None of the scores had LRs that would be considered helpful for ruling-in or ruling-out SBI in low-prevalence settings (LR+ greater 5 or LR- lower than 0.2). Table 5results of external validation of prediction rules and guidelines to rule-in and rule-out serious bacterial infectionPrediction rule/guidelinen/N^a^%test positive% sensitivity (95% CI)% specificity (95% CI)Likelihood ratio (95% CI)positivenegativeBleeker126/73162.9%81.0 (73.0--87.4)40.8 (36.9--44.9)1.37 (1.23--1.52)0.47 (0.32--0.68)Thayyil162/10015.2%31.7 (24.7--39.4)74.4 (71.3--77.4)1.24 (0.96--1.60)0.92 (0.82--1.03)Lab Score126/73168.3%70.6 (61.9--78.4)32.2 (28.5--36.1)1.04 (0.92--1.18)0.91 (0.68--1.22) Rotterdam fever model 2.5% risk161/98566.50%77.3 (70.1--83.5)35.6 (32.4--39.0)1.21 (1.10--1.32)0.64 (0.47--0.86) 5% risk161/98555.53%69.9 (62.3--76.9)47.3 (43.9--50.8)1.33 (1.18--1.50)0.64 (0.50--0.81) 15% risk161/98536.24%49.7 (41.8--57.6)66.4 (63.1--69.6)1.48 (1.23--1.78)0.76 (0.65--0.89)IMCI164/100530.8%36.7 (29.4--44.6)70.3 (67.1--73.4)1.22 (0.97--1.55)0.90 (0.79--1.02)iCCM164/100530.5%36.7 (29.4--44.6)70.7 (67.5--73.7)1.25 (1.00--1.57)0.89 (0.79--1.01)ALMANACH164/100544.3%63.3 (55.4--70.6)63.2 (59.8--66.4)1.72 (1.48--1.99)0.58 (0.47--0.71)NICE164/100576.0%83.7 (77.2--89.0)25.5 (22.6--28.6)1.12 (1.04--1.22)0.64 (0.44--0.92)AAEP164/100541.7%68.1 (60.4--75.1)63.5 (60.2--66.8)1.87 (1.63--2.14)0.50 (0.40--0.63)^a^Number of children with SBI out of all children included into validation. N represents the total number of children for which all variables of the prediction rule were recorded (please also refer to Additional file [2](#MOESM2){ref-type="media"}: Table S1)

Figure [2](#Fig2){ref-type="fig"} illustrates the overlap between SBI classification (reference) and antibiotic treatment classifications by the score. The Bleeker score and NICE guideline achieved the highest proportion of correct classifications (14% of the total population) but at the expense of many unnecessary antibiotic prescriptions: 49 and 62% of patients, respectively. IMCI, iCCM and the Thayyil score resulted in the lowest proportion of correct classifications (6% of patients). Fig. 2Overlap of serious bacterial infection classification (blue) and antibiotic treatment classification per rule or guideline (pink). The blue circles represent the percentage of patients with a SBI identified in the validation dataset. The pink circles illustrate the percentage of patients that tested 'positive' in the dataset per the rule or guideline. The overlap represents the percentage of patients with SBI who were correctly classified as such according to the rule

Figure [3](#Fig3){ref-type="fig"} shows the missed cases of SBI according to different classifications. Not surprisingly, IMCI, iCCM, and AAEP missed very few pneumonia cases since the classifications used by these guidelines were part of the outcome definition (see [Sensitivity analyses](#Sec14){ref-type="sec"}). Similarly, missed UTI cases were fewer in scores that use urine laboratory testing. All rules and guidelines, besides the Rotterdam model at low cutoff and the NICE guideline, missed a large amount of patients with bacteremia (50--75% of bacteremia cases). Fig. 3Missed cases of serious bacterial infections (SBI)

Sensitivity analyses {#Sec14}
--------------------

Applying the rule only to the age group for which it was originally designed, resulted in a significantly higher specificity for the Bleeker rule, Thayyil score, Lab Score and AAEP guideline (Table [6](#Tab6){ref-type="table"}). We found similar results for relevant scores when including patients without pneumonia or without malaria only, when compared to the full validation dataset (Table [6](#Tab6){ref-type="table"}). The specificity of ALMANACH was increased when applying to patients without UTI only. There was no significant change in the performance of prediction rules originally derived for children with fever without source when we compared the full dataset with the dataset containing children with fever without source only (Table [6](#Tab6){ref-type="table"}). Table 6Results of sensitivity analysesPrediction rule/guidelinen/N%test positive% sensitivity (95% CI)% specificity (95% CI)Likelihood ratio (95% CI)positivenegativeDerivation age-group only Bleeker88/50746.5%72.7 (62.2--81.7)58.9 (54.1--63.7)1.77 (1.49--2.10)0.46 (0.33--0.66) Thayyil124/7775.4%11.3 (6.3--18.2)95.7 (93.9--97.1)2.63 (1.43--4.86)0.93 (0.87--0.99) Lab Score88/50754.2%58.0 (47.0--68.4)46.5 (41.7--51.4)1.08 (0.89--1.32)0.90 (0.69--1.18) Rotterdam fever model  2.5% risk161/98566.50%77.6 (70.4--83.8)35.7 (32.4--39.1)1.21 (1.10--1.33)0.63 (0.46--0.85)  5% risk161/98555.53%70.2 (62.5--77.1)47.3 (43.9--50.8)1.33 (1.18--1.50)0.63 (0.49--0.81)  15% risk161/98536.24%49.7 (41.7--57.7)66.4 (63.0--69.6)1.48 (1.23--1.77)0.76 (0.65--0.89) IMCI154/94126.1%31.8 (24.6--39.8)70.0 (71.8--78.0)1.27 (0.98--1.65)0.91 (0.81--1.02) iCCM154/94125.8%31.8 (24.6--39.8)75.3 (72.2--78.3)1.29 (0.99--1.68)0.90 (0.81--1.02) ALMANACH154/94140.5%64.9 (56.8--72.4)64.3 (60.8--67.6)1.82 (1.57--2.11)0.55 (0.44--0.68) NICE154/94174.4%82.5 (75.5--88.1)27.2 (24.1--30.4)1.13 (1.04--1.23)0.64 (0.45--0.93) AAEP122/75622.5%58.2 (48.9--67.1)84.4 (81.3--87.1)3.73 (2.95--4.72)0.50 (0.40--0.61)Patients without pneumonia only IMCI133/97428.7%21.8 (15.1--29.8)70.2 (66.9--73.2)0.73 (0.52--1.02)1.11 (1.01--1.23) iCCM133/97428.4%21.8 (15.1--29.8)70.5 (67.3--73.6)0.74 (0.53--1.04)1.11 (1.00--1.23) ALMANACH133/97443.5%66.9 (58.2--74.8)60.2 (56.8--63.5)1.68 (1.45--1.94)0.55 (0.43--0.70) AAEP133/84139.9%62.4 (53.6--70.7)63.6 (60.3--66.9)1.72 (1.46--2.01)0.59 (0.47--0.74)Patients without UTI only Bleeker67/67260.2%70.1 (57.7--80.7)40.8 (36.9--44.9)1.19 (1.00--1.40)0.73 (0.50--1.07) Lab Score67/67267.9%68.7 (56.2--79.4)32.2 (28.5--36.1)1.01 (0.85--1.20)0.97(0.67--1.41) ALMANACH107/94631.8%48.6 (38.8--58.5)70.3 (67.1--73.4)1.64 (1.31--2.04)0.73 (0.60--0.88) AAEP107/94639.4%62.6 (52.7--71.8)63.5 (60.2--66.8)1.72 (1.45--2.04)0.59 (0.46--0.76)Patients with negative malaria test only Bleeker119/64360.4%79.8 (71.5--86.6)43.9 (39.6--48.3)1.42 (1.26--1.60)0.46 (0.32--0.67) Thayyil153/89724.0%31.4 (24.1--39.4)77.6 (74.4--80.5)1.40 (1.07--1.83)0.88 (0.79--0.99) Lab Score119/64265.4%68.9 (59.8--77.1)35.4 (31.3--39.6)1.07 (0.93--1.22)0.88 (0.66--1.18) Rotterdam fever model  2.5% risk152/88162.9%76.3 (68.7--82.8)39.9 (36.3--43.6)1.27 (1.14--1.41)0.59 (0.44--0.80)  5% risk152/88151.1%68.4 (60.4--75.7)52.5 (48.8--56.2)1.44 (1.26--1.65)0.60 (0.47--0.77)  15% risk152/88132.1%48.0 (39.9--56.3)71.2 (67.8--74.5)1.67 (1.36--2.04)0.73 (0.62--0.86)Patients with fever without source only for scores that were derived in children with fever without source Bleeker73/31569.8%80.8 (69.9--89.1)33.5 (27.6--39.8)1.21 (1.05--1.40)0.57 (0.35--0.95) Thayyil77/36730.8%27.3 (17.7--38.6)68.3 (62.6--73.6)0.86 (0.58--1.28)1.07 (0.91--1.25) Lab Score73/31472.2%71.2 (59.4--81.2)27.4 (21.9--33.5)0.98 (0.83--1.16)1.05 (0.69--1.59)

Discussion {#Sec15}
==========

In the outpatient setting in Tanzania, none of the prediction rules and guidelines examined had sufficient diagnostic accuracy to detect children with SBI. IMCI and iCCM, which were designed to be sensitive for detecting SBI in these settings, actually had very low sensitivities when applied to our validation dataset. The Bleeker score, NICE guidelines, and Rotterdam Model at low cutoff showed the highest, though moderate, sensitivity, indicating a value in ruling-out children for SBI in low-prevalence, peripheral health care settings. However, at the same time, they classified many children as having a SBI, i.e. requiring antibiotic treatment. The use of such rules or guidelines would hence require further confirmatory testing to avoid antibiotic over-prescription. Rules that use a combination of clinical and laboratory testing, the Bleeker score, Rotterdam Model, ALMANACH, and AAEP guideline had better performance compared to rules and guidelines using only clinical and or laboratory elements. We performed several sensitivity analyses to estimate whether differences in demographic and ecological characteristics between the derivation and validation population had an influence on the diagnostic accuracy. Importantly, we did not find significant differences in the performance of the SBI scores in patients of the targeted age group or patients without malaria only when compared with the entire study population.

To our knowledge, this was the first comprehensive attempt to examine the accuracy of IMCI and other prediction rules and guidelines in diagnosing SBI in a tropical, low-resource outpatient setting against a robust gold standard. Besides one 1995 study in Bangladesh that performed blood cultures and CXR \[[@CR12]\], guidelines developed for low-resource-settings (IMCI, iCCM, ALMANACH) have never been validated against carefully established gold standards (contrary to expert opinion). Overall guidance for SBI other than pneumonia and dysentery are lacking in the current IMCI guidelines, which specifies only "to give antibiotic treatment if a bacterial source of infection is identified". But identifying such bacterial infections without guidance is challenging for low-level health workers. Alarmingly, the sensitivity of IMCI was very low---IMCI was originally designed to be very sensitive at the expense of being specific for detection of infections requiring antibiotic treatment. The diagnostic accuracy of ALMANACH sought to address these challenges through adding urinary dipstick testing and a clinical predictor for typhoid \[[@CR41]\]. Indeed, sensitivity was improved but at the cost of a lower specificity in our dataset. Generally, very few studies have validated outpatient prediction rules and clinical guidelines for SBI systematically. One recent study validated systematically four clinical prediction rules and two national guidelines retrospectively across datasets from primary care and emergency departments in Europe \[[@CR33]\]. The diagnostic accuracy of the prediction rules and guidelines also validated in our study were generally higher. This may be due to the fact that the original derivation population was more similar to the validation datasets of the European validation study. Other studies in the African setting have evaluated scores for SBI and death at the inpatient level. Nadjm et al. evaluated prospectively the accuracy of WHO hospital-level clinical criteria for presumptive antibiotic treatment in detecting SBI (positive blood and/or cerebrospinal fluid culture) among 3639 admitted children in Tanzania \[[@CR42]\]. The sensitivity was higher when compared to IMCI in our study (67.4, 95% CI 65.9--69.0%), at a lower specificity of 51.5% (95% CI 49.9--53.1%). Reported sensitivities of a similar study by Berkley at al. were even higher \[[@CR43]\]. However, the comparison of results from these studies with the present analysis is extremely limited by the difference in prevalence of SBI in the inpatient versus outpatient setting, and the restricted number of investigations for SBI performed (blood and cerebrospinal fluid culture only). Conroy et al. validated three scores to predict in-hospital (and not outpatient) mortality among Ugandan children with fever \[[@CR44]\]. Through mortality is a relevant and robust outcome, its use at the outpatient level, where death is a rare event, is difficult.

This study has several limitations. Only a single dataset from was available for validation, which limits the generalizability of our findings. However, rates of bacteremia in our study were similar to other studies conducted at primary care level around the same time and the dataset is likely representative of the typical case-mix \[[@CR45]\]. There are multiple sources of heterogeneity. The most obvious one is the difference in setting for all prediction rules and two out of the four guidelines. Difference in bacterial pathogens, such as typhoid and rickettsial diseases, substantially limits the applicability of "Northern" guidelines to tropical settings. Differences in recorded values between the derivation and validation datasets is another limitation for this analysis. Though this study used robust, predefined reference criteria with extensive microbiological testing, the gold standards for SBI certainly remain imperfect \[[@CR46]\]. For pneumonia end-point consolidation on CXR has been used though it is known that only an (unknown) percentage of consolidations are of bacterial origin, and that viral pneumonia may produce abnormalities on CXR as well \[[@CR47]\]. As a result, test diagnostic accuracy may be biased in both directions. The diagnostic accuracy of all available tests for typhoid is poor \[[@CR48]\] and hence the typhoid classification (combination of rapid test and blood and stool cultures), was certainly suboptimal. Consequently, the sensitivity of guidelines to detect SBI may have been underestimated. Despite the comprehensive set of clinical and laboratory predictors in the validation dataset, we were able to validate only four of the nine prediction rules plus all guidelines and had to use proxies for several predictors. For the Bleeker score, for example, "ill-appearance" was likely underestimated in our validation dataset since the variables "lethargy, and very sick child" refer to a sicker child. On the other hand, using the urine leucocyte dipstick test instead of the urine WBC likely overestimated the presence of UTI. We did not impute missing data as the "missing at random assumption" could not be assumed for the validation dataset; this may have influenced our estimates of performance for those rules that use urinary dipstick testing where we encountered a large percentage of missing data in the validation set.

Our findings have several implications for clinical practice and research in low-resource settings. First, the efforts should be made to increase the sensitivity of current screening tools for SBI. As it was intended for IMCI, clinical guidelines should have high sensitivity as the access to care in such settings is difficult, referral to higher level of care may be delayed, and safety-netting is not always available. Guidelines should be presented as stepwise decision algorithms, which follow the logical flow of the actual diagnostic process \[[@CR46]\]. This is especially true for low-resource settings where health care providers with limited training benefit from clinical decision algorithms \[[@CR49]\]. Within such algorithms, simple but sensitive clinical criteria will be needed to quickly rule-out children with SBI. This could then be followed by a more specific second-step laboratory testing, such as point-of-care biomarkers, in order to avoid unnecessary antibiotic treatment. However, no algorithm will have perfect diagnostic accuracy making safety netting (follow-up) an important component of clinical care. Third, disease management algorithms should undergo careful external validation before implementation. Ideally, such validation studies should be performed against clinical outcome, and not against a microbiological reference standard only as it is difficult to establish a valid microbiological reference standard. This could either be achieved through composite reference standards including clinical patient follow-up \[[@CR46]\], or through the evaluation of decision rules through randomized clinical trials \[[@CR32]\].

Viral infections, such as bronchiolitis, may cause severe disease. The guidance on supportive measures for viral infections by a clinical algorithm designed for the low-resource outpatient setting may be become equally important with declining prevalence of SBI. ALMANACH, for example, achieved better clinical outcome in a validation study against routine care in Tanzania \[[@CR50]\].

Conclusions {#Sec16}
===========

None of the examined prediction rules and guidelines had sufficient diagnostic accuracy to detect children with SBI in a tropical, low-resource setting. IMCI and iCCM, which were designed to be sensitive for detecting SBI in these settings, actually had very low sensitivities when applied to our validation dataset. Some prediction rules and guidelines had higher sensitivity and hence showed promise to rule-out SBI in our dataset. However, they also classified a larger number of patients as having a SBI, calling for additional second-stage testing, such as point-of care inflammatory markers, and tests for severity such as oximetry and hemoglobin. New clinical algorithms should undergo careful external validation studies against clinical outcome before implementation in routine care.
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AAEP

:   American Academy of Emergency Physicians

CI

:   Confidence interval

CRP

:   C-reactive protein

CXR

:   Chest radiograph

HIV

:   Human immunodeficiency virus

iCCM

:   Integrated Community Case Management guidelines

IMCI

:   Integrated Management of Childhood Illnesses

LR

:   Likelihood ratio

SBI

:   Serious bacterial infection

UTI

:   Urinary tract infection

WHO

:   World Health Organization
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